CAPhO 2026 Mastering PIK3CA Targeted Therapy in HR+/HER2- Breast Cancer Pharmacists Leading the Way

Hoffmann La Roche Limited Sponsored Symposium

Precision oncology is changing how advanced HR+/HER2− breast cancer is managed — and oncology pharmacists are central to safe, effective delivery.

Experts will break down the clinical relevance of PIK3CA mutations, where targeted therapies fit in the treatment pathway, and what this means for your daily practice. Gain practical, pharmacist-focused strategies for patient counselling, monitoring, and preventing and managing treatment-related adverse events.

Come for a mocktail. Leave with concise, practice-ready tips you can use with patients the very next day